Ziobrowska-Bech, A., Winther-Larsen, A., Kremke, B., Parkner, T. & Soendersoe Knudsen, C. (2019).
Reference limits for GAD65 and IA-2 autoantibodies by chemiluminescence immunoassay in Northern European adults and children.
Scandinavian Journal of Clinical and Laboratory Investigation,
79(1-2), 123-125.
https://doi.org/10.1080/00365513.2019.1566566
Zinzani, P. L.
, d'Amore, F., Bombardieri, E., Brammer, C., Codina, J. G., Illidge, T., Jurczak, W., Linkesch, W., Morschhauser, F., Vandenberghe, E. & Van Hoof, A. (2008).
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
European Journal of Cancer,
44(3), 366-73.
https://doi.org/10.1016/j.ejca.2007.12.008Zinzani, P., Coiffier, B., Radford, J., Caballero, D., Fields, P., Chamuleau, M.
, D'Amore, F. A., Haioun, C., Thieblemont, C., Barca, E., Garcia, C., Johnson, PW., Van Imhoff, G., Saunders, A., Dwyer, K. & Morschhauser, F. (2014).
A phase II open-label, multi-center study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients with previously treated peripheral t-cell lymphoma (PTCL).
Blood,
124(21).
Zinzani, P. L., Karlin, L., Radford, J., Caballero, D., Fields, P., Chamuleau, M. E. D.
, d'Amore, F., Haioun, C., Thieblemont, C., González-Barca, E., Grande García, C., Johnson, P. W., van Imhoff, G. W., Ng, T., Dwyer, K. & Morschhauser, F. (2016).
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
Haematologica,
101(10), e407-e410.
https://doi.org/10.3324/haematol.2016.146977Zinyama-Gutsire, R., Gomo, E., Kallestrup, P.
, Erikstrup, C., Ullum, H., Butterworth, A. E., Munyati, S. & Mduluza, T. (2009).
Downregulation of MIP-1alpha/CCL3 with praziquantel treatment in Schistosoma haematobium and HIV-1 co-infected individuals in a rural community in Zimbabwe.
B M C Infectious Diseases,
9, 174.
https://doi.org/10.1186/1471-2334-9-174